ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
12. September 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-4452)...